The ARRONAX project

Current Radiopharmaceuticals

Volumn 4, Issue 3, 2011, Pages 186-196

  Haddad, Ferid ^a,b   Barbet, Jacques ^a,b   Chatal, Jean François ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b GIP ARRONAX   (France)

Author keywords

Astatine 211; High energy cyclotron; High intensity beam; Radionuclide production; Targeted alpha therapy

Indexed keywords

ASTATINE 211; COPPER 64; COPPER 67; GALLIUM 68; GERMANIUM; GERMANIUM 68; POLONIUM; POLONIUM 211; RUBIDIUM 82; SCANDIUM; SCANDIUM 44; SCANDIUM 47; STRONTIUM 82; UNCLASSIFIED DRUG;

ALPHA RADIATION; ARTICLE; CYCLOTRON; IRRADIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON RADIATION; RADIOBIOLOGY; RADIOISOTOPE THERAPY; RADIOLYSIS;

EID: 79959465191     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104030186     Document Type: Article

References (71)

1. 68Ga-labeled peptides in tumor imaging. J. Nucl. Med., 2005, 46, 172-178.
2. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J. Nucl. Med., 1999, 40(2), 302-310.
3. 124I PET and 3-dimensionalinternal dosimetry (3D-ID) software. J. Nucl. Med., 2004, 45(8), 1366-1372.
4. Barbet, J.; Chatal, J.F.; Gauche, F.; Martino, J. Which radionuclides will nuclear oncology need tomorrow? Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(6):627-630.
5. McDevitt, M.R.; Sgouros, G.; Finn, R.D.; Humm, J.L.; Jurcic, J.G.; Larson, S.M.; Scheinberg, D.A. Radioimmunotherapy with alphaemitting nuclides. Eur. J. Nucl. Med., 1998, 25(9), 1341-1351.
6. 231Pa. Analytical Chemistry, 2008, 80(22), 8763-8770.
7. Pfost, B.; Morgenstern, A.; Seidl, C.; Bruchertseifer, F.; Autenrieth, M.; Apostolidis, C.; Abbas, K.; Senekowitsch-Schmidtke, R. Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFRMAb, J. Nucl. Med., 2009, 50, 36.
8. Shankar, L.K.; Hoffman, J.M.; Bacharach, S.; Graham, M.M.; Karp, J.; Lammertsma, A.A.; Larson, S.; Mankoff, D.A.; Siegel, B.A.; van den Abbeele, A.; Yap, J.; Sullivan, D. National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J. Nucl. Med., 2006, 47, 1059-1066.
9. Lee, F.T.; Scott, A.M. Immuno-PET for tumor targeting. J. Nucl. Med., 2003, 44(8), 1282-1283.
10. Verel, I.; Visser, G.W.; van Dongen, G.A. The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med., 2005, 46, 164-171.
11. Boubaker, A.; Bischof Delaloye, A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 388-402.
12. Goldenberg, D.M.; Sharkey, R.M. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q. J. Nucl. Med. Mol. Imaging, 2006, 50(4), 248-64.
13. de Jong, M.; Kwekkeboom, D.; Valkema, R.; Krenning, E.P. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(3), 463-469.
14. Goldenberg, D.M.; Sharkey, R.M.; Paganelli, G.; Barbet, J.; Chatal, J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol., 2006, 24(5), 823-834.
15. Kolsky, K.L.; Joshi, V.; Mausner, L.F.; Srivastava, S.C. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl. Radiat. Isot., 1998, 49, 1541-1549.
16. DeNardo, G.L.; DeNardo, S.J.; Kukis, D.L.; O'Donnell, R.T.; Shen, S.; Goldstein, D.S.; Kroger, L.A.; Salako, Q.; DeNardo, D.A.; Mirick, G.R.; Mausner, L.F.; Srivastava, S.C.; Meares, C.F. Maximum tolerated dose of 67-Cu-2IT-BAT-LYM1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res., 1998, 18, 2779-2788.
17. Haddad, F.; Ferrer, L.; Guertin, A.; Carlier, T.; Michel, N.; Barbet, J.; Chatal, J.F. ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1377-1387.
18. th International Symposium of Capture Gamma-Ray Spectroscopy and Related Topics, Budapest, Hungary, October 1996. Data extracted from the NUDAT database, version 2006, http://www.nndc.bnl.gov/nudat2/.
19. Dearling, J.L.; Lewis, J.S.; Mullen, G.E.; Rae, M.T.; Zweit, J.; Blower, P.J. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur. J. Nucl. Med., 1998, 25, 788.
20. Kenneth, A., Krohn, K.A.; Link, J.M.; Mason, R.P. Molecular Imaging of Hypoxia. J. Nucl. Med., 2008, 49, 129-148.
21. Mees, G.; Dierckx, R.; Vangestel, C.; van de Wiele, C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 1674-1686.
22. 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl. Med. Biol., 2003, 30, 417.
23. 64Cu: A comprehensive evaluation. Radiochimica Acta, 2009, 97, 669-686.
24. 120gI at a small-sized cyclotron. Appl. Radiat. Isot., 2003, 58(1), 69-78.
25. 64Cu using a 12 MeV cyclotron. Nucl. Med. Biol., 2003, 30(5), 535-539.
26. Holland, J.P.; Sheh, Y.; Lewis, J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol., 2009, 36(7), 729-739.
27. Abanades, A.; Aleixandre, J.; Andriamonje, S. Results from the TARC experiment: spallation neutron phenomenology in lead and neutron-driven nuclear transmutation by adiabatic resonance crossing. Nucl. Instr. Meth. A, 2002, 478, 577-730.
28. Abbas, K.; Buono, S.; Burgio, N. Development of an accelerator driven neutron activator for medical radioisotope production. Nucl. Instr. Meth. A, 2009, 601, 223-228.
29. Buono, S.; Maciocco, L.; Burgio, N.; Santagata, A.; Abas, K.; Simonelli, F. A cyclotron-driven neutron activator for the production of β-emitting radioisotopes for brachytherapy. Physics for Health in Europe Workshop (February 2-4, 2010, Geneva, Switzerland), http://www.adacap.com/research_pubblications.php?l=eng&c=000 11.
30. Ishii, K.; Morita, S. Theoretical estimation of PIXE detection limits. Nucl. Instr. Meth. B, 1988, 34, 209-216.
31. Denker, A.; Opitz-Coutureau, J.; Griesser, M. Non-destructive analysis of coins using high-energy PIXE. Nucl. Instr. Meth. B, 2004, 226, 163-171.
32. Koumeir, C.; Haddad, F.; Metivier, V.; Servagent, N.; Michel, N. A new facility for high energy PIXE at the ARRONAX Facility. Proceeding of European Conference on X-ray spectrometry 20-25 June, 2010, Figueira da Foz, Coimbra, Portugal.
33. Le Guludec, D.; Lautamäki, R.; Knuuti, J.; Bax, J.J.; Bengel, F.M. European Council of Nuclear Cardiology, Present and future of clinical cardiovascular PET imaging in Europe-a position statement by the European Council of Nuclear Cardiology (ECNC). Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1709-1724.
34. Special issue on the Strontium-82/Rubidium-82 generator. Appl. Radiat. Isot., 1987, 38(3).
35. Sanchez-Crespo, A.; Andreo, P.; Larsson, S.A. Positron flight in human tissues and its influence on PET image spatial resolution. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(1), 44-51.
36. Smith-Jones, P.M.; Stolz, B.; Bruns, C.; Albert, R.; Reist, H.W.; Fridrich, R.; Mäcke, H.R. Gallium-67/gallium-68-[DFO]-octreotide-a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J. Nucl. Med., 1994, 35(2), 317-325.
37. 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med., 2001, 28(12), 1751-1757.
38. 68Ga-DOTA-DPhe1-Tyr3-octreotide kinetics in patients with meningiomas. J. Nucl. Med., 2005, 46(5), 763-769.
39. Klivényi, G.; Schuhmacher, J.; Patzelt, E.; Hauser, H.; Matys, R.; Moock, M.; Regiert, T.; Maier-Borst, W. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J. Nucl. Med., 1998, 39(10), 1769-1776.
40. Schuhmacher, J.; Kaul, S.; Klivényi, G.; Junkermann, H.; Magener, A.; Henze, M.; Doll, J.; Haberkorn, U.; Amelung, F.; Bastert, G. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res., 2001, 61(9), 3712-3717.
41. 188W. IAEA Radioisotopes and Radiopharmaceuticals Series 1436, 2010.
42. th Int. conf. on cyclotrons and their applications; Rifuggiato, D.; Piazza L.A.C.; Pressola C.D.B. di Ragusa, Eds.; 2008, 257.
43. Loch, C.; Maziere, B.; Comar, D. A new preparation of Ge-68. Int. J. Appl. Rad. Isot., 1982, 33, 267-270.
44. Cheng, W.L.; Jao, Y.; Lee, C.S. Preparation of Ge-68/Ga-68 generator with a binary Ga/Ag electrodepositions as solid target. J. Radioanal. Nucl. Chem., 2000, 245, 25-30.
45. Okamoto H. Ag-Ga (silver-gallium). J. Phase Equilibria, 2001, 22, 687-687.
46. Anderson, C.J.; Connett, J.M.; Schwarz, S.W.; Rocque, P.A.; Guo, L.W.; Philpott, G.W.; Zinn, K.R.; Meares, C.F.; Welch, M.J. Copper-64-labeled antibodies for PET imaging. J. Nucl. Med., 1992, 33(9), 1685-1691.
47. Philpott, G.W.; Schwarz, S.W.; Anderson, C.J.; Dehdashti, F.; Connett, J.M.; Zinn, K.R.; Meares, C.F.; Cutler, P.D.; Welch, M.J.; Siegel, B.A. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med., 1995, 36(10), 1818-1824.
48. Shen, S.; DeNardo, G.L.; DeNardo, S.J.; Salako, Q.; Morris, G.; Banks, D.; Yuan, A.; DeNardo, D.A. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy. J. Nucl. Med., 1996, 37(1), 146-150.
49. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(7), 764-770.
50. McCarthy, D.W.; Shefer, R.E.; Klinkowstein, R.E.; Bass, L.A.; Margeneau, W.H.; Cutler, C.S.; Anderson, C.J.; Welch, M.J. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl. Med. Biol., 1997, 24(1), 35-43.
51. 64Cu produced using enriched nickel target. Radiohimica Acta, In press.
52. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J. Nucl. Med., 1999, 40, 302-310.
53. Novak-Hofer, I.; Schubiger, P.A. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(6), 821-830.
54. Mausner, L.F.; Kolsky, K.L.; Joshi, V.; Srivastava, S.C. Radionuclide development at BNL for nuclear medicine therapy. Appl. Radiat. Isot., 1998, 49(4), 285-294.
55. Kolsky, K.L.; Joshi, V.; Mausner, L.F.; Srivastava, S.C. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Appl. Radiat. Isot., 1998, 49, 1541-1549.
56. 44Sc for clinical application. Appl. Radiat. Isot., 2010, 68(9), 1636-1641.
57. + gamma coincidences from Sc-44 radio-nuclide with liquid xenon as detection medium. Nucl. Instr. Meth. A, 2007, 571, 142-145.
58. McDevitt, M.R.; Sgouros, G.; Finn, R.D.; Humm, J.L.; Jurcic, J.G.; Larson, S.M.; Scheinberg, D.A. Radioimmunotherapy with alphaemitting nuclides. Eur. J. Nucl. Med. Mol. Imaging, 1998, 25, 1341-1351.
59. Mulford, D.A.; Scheinberg, D.A.; Jurcic, J.G. The promise of targeted alpha-particle therapy. J. Nucl. Med., 2005, 46, 199-204.
60. Couturier, O.; Supiot, S.; Degraef-Mougin, M.; Faivre-Chauvet, A.; Carlier, T.; Chatal, J. F,; Davodeau, F.; Cherel, M. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 601-614.
61. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl. Med. Biol., 1995, 22, 45-54.
62. Welch, M.J. Potential and pitfalls of therapy with alpha-particles. J. Nucl. Med., 2005, 46, 1254-1255.
63. Chérel, M.; Davodeau, F.; Kraeber-Bodere, F.; Chatal, J.F. Current status and perspectives in alpha radioimmunotherapy. Q. J. Nucl. Med. Mol. Imaging, 2006, 50, 322-329.
64. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med., 2008, 49(1), 30-38.
65. 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin. Cancer Res., 1999, 5, 3165-3170.
66. Supiot, S.; Faivre-Chauvet, A.; Couturier, O.; Heymann, M.F.; Robillard, N.; Kraeber-Bodéré, F.; Morandeau, L.; Mahé, M.A.; Chérel, M. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer, 2002, 94, 1202-1209.
67. Alliot, C.; Cherel, M.; Barbet, J.; Sauvage, T.; Montavon, G. Extraction of astatine-211 in diisopropylether (DIPE). Radiochimica Acta, 2009, 97, 161-165.
68. Bourgeois, M.; Guerard, F.; Alliot, C.; Mougin-Degraef, M.; Rajerison, H.; Le Saec, P.; Gestin, J.F.; Cherel, M.; Barbet, J.; Faivre-Chauvet, A. Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction. J. Labelled Compounds Radiopharm., 2008, 51, 379-383.
69. Champion, J.; Alliot, C.; Renault, E.; Mokili, B.M.; Chérel, M.; Galland, N.; Montavon, G. Astatine standard redox potentials and speciation in acidic medium. J. Phys. Chem. A, 2010, 114, 576-582.
70. 64Cu. Nucl. Instr. Meth. B, 2005, 240, 625.
71. Mausner, L.F.; Hock, J.C. Target design consideration for isotope production with high intensity 200 MeV protons. Nucl. Inst. Meth. A, 1997, 397, 18.